Irving Kirsch1. 1. Department of Psychology, University of Hull, Cottingham Road, Hull, HU6 7RX, United Kingdom. i.kirsch@hull.ac.uk
Abstract
AIMS: To evaluate new generation antidepressants in relation to the placebo response. METHODS: I review meta-analyses in which response to antidepressant medication and response to placebo were calculated. RESULTS: All but one of these meta-analyses included unpublished as well as published trials. Most trials failed to show a significant advantage of SSRIs over inert placebo, and the differences between drug and placebo are not clinically significant for most depressed patients. Documents obtained from the U.S. Food and Drug Administration (FDA) revealed an explicit decision to keep this information from the public and from prescribing physicians. CONCLUSIONS: Because they do not incur drug risks, exercise and psychotherapy, which show at benefits at least equal to those of antidepressants, may be a better treatment choice for depressed individuals.
AIMS: To evaluate new generation antidepressants in relation to the placebo response. METHODS: I review meta-analyses in which response to antidepressant medication and response to placebo were calculated. RESULTS: All but one of these meta-analyses included unpublished as well as published trials. Most trials failed to show a significant advantage of SSRIs over inert placebo, and the differences between drug and placebo are not clinically significant for most depressedpatients. Documents obtained from the U.S. Food and Drug Administration (FDA) revealed an explicit decision to keep this information from the public and from prescribing physicians. CONCLUSIONS: Because they do not incur drug risks, exercise and psychotherapy, which show at benefits at least equal to those of antidepressants, may be a better treatment choice for depressed individuals.
Authors: A M Möller-Leimkühler; H-J Möller; W Maier; W Gaebel; P Falkai Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-02-13 Impact factor: 5.270
Authors: Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk Journal: Inflammopharmacology Date: 2012-01-24 Impact factor: 4.473
Authors: Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk Journal: Mol Neurobiol Date: 2015-05-02 Impact factor: 5.590
Authors: T Munder; C Flückiger; F Leichsenring; A A Abbass; M J Hilsenroth; P Luyten; S Rabung; C Steinert; B E Wampold Journal: Epidemiol Psychiatr Sci Date: 2018-07-30 Impact factor: 6.892
Authors: Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11 Impact factor: 5.270
Authors: Alison Karasz; Christopher Dowrick; Richard Byng; Marta Buszewicz; Lucia Ferri; Tim C Olde Hartman; Sandra van Dulmen; Evelyn van Weel-Baumgarten; Joanne Reeve Journal: Br J Gen Pract Date: 2012-01 Impact factor: 5.386
Authors: Jennifer L Lapierre; Peter O Kosenko; Tohru Kodama; John H Peever; Lev M Mukhametov; Oleg I Lyamin; Jerome M Siegel Journal: J Neurosci Date: 2013-02-06 Impact factor: 6.167